Zoetis (NYSE: ZTS) reported Q4 EPS of $0.92, $0.04 better than the analyst estimate of $0.88. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.64 billion.

• For Fourth Quarter 2019, Zoetis Reports Revenue of $1.7 Billion, Growing 7%, and Net Income of $384 Million, or $0.80 per Diluted Share, on a Reported Basis
  • Reports Adjusted Net Income of $440 Million, or Adjusted Diluted EPS of $0.92, for Fourth Quarter 2019
  • Delivers 9% Operational Growth in Revenue and 13% Operational Growth in Adjusted Net Income for Fourth Quarter 2019

EXECUTIVE COMMENTARY

“In 2019, Zoetis delivered another year of strong growth and market leadership thanks to our diverse and durable portfolio and commitment to continuous innovation,” said Kristin Peck, Chief Executive Officer of Zoetis. “We grew revenue 10% operationally, which is once again above market growth in a competitive, global sector. We also grew our adjusted net income faster than revenue, at 14% operationally, continuing to achieve our goal of growing profitability faster than revenue over the long term.”

“Looking ahead in 2020, we are excited about the launch of Simparica® Trio, our new triple combination parasiticide for dogs, and we will be heavily focused on bringing this key innovation to customers around the world,” said Peck. “Additionally, we will continue to advance our pipeline with innovations in parasiticides, monoclonal antibodies and vaccines; support our latest product launches and lifecycle innovations across the portfolio; and invest in newer growth areas for us such as diagnostics, digital and data analytics. For full year 2020, we expect operational growth of 7% to 9.5% in revenue and 8% to 11% in adjusted net income. As the new CEO of Zoetis, I look forward to carrying on the company’s successful formula of customer focus, innovation and execution, as we continue to deliver on our long-term value proposition to shareholders.”

GUIDANCE:

Zoetis sees FY2020 EPS of $3.90-$4.00, versus the consensus of $4.01. Zoetis sees FY2020 revenue of $6.65-6.8 billion, versus the consensus of $6.7 billion.

For earnings history and earnings-related data on Zoetis (ZTS) click here.